Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.53 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.53 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.50 |
| ▸ | GSR | P00390 | 2/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | GRM8 | O00222 | 1/20 | 0.48 |
| ▸ | GRM6 | O15303 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.48 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.48 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.48 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL6419228 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL7717425 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL307009 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL8023215 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL8074635 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL28092959 | 1.00 | GLRA1 (0.53) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL3655651 | 0.97 | GLRA1 (0.50) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL425953 | 0.97 | GLRA1 (0.50) | GLRA1SLC6A9OR51E2GRIK1GRIK2 | |
| Aspartic Acid SCHEMBL1526976 | 0.92 | GRIK1 (0.56) | GRIK1GRIK2GRM1GRM2GSR | |
| D-Aspartate SCHEMBL145539 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023094987-A1 | A DRUG DELIVERY COMPOSITION FOR TREATING MYOCARDIAL INFRACTION (MI) | GHAMKHARI ALIYEH (IR) | 2023-06-01 | — | — | WO | claimed |
| CN-112725803-B | Titanium etching solution for wafer level packaging | 江苏奥首材料科技有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-112725803-A | Titanium etching solution for wafer level packaging | 江苏奥首材料科技有限公司 | 2021-04-30 | — | — | CN | claimed |
| CN-107354139-A | Wheat ALS muteins, nucleic acid and its application | 江苏省农业科学院 | 2017-11-17 | — | — | CN | claimed |
| WO-2002086153-A1 | DETERMINING RESISTANCE TO A $G(b)-LACTAM-CONTAINING ANTIBIOTIC BY COMPARING THE RATIO OF TWO $G(b)-LACTAMASE GENES | DIATECH PTY LTD (AU) | 2002-10-31 | — | — | WO | claimed |
| US-4725279-A | BURN DRESSINGS; POLYMERIC SUBSTRATE TREATED WITH ACTIVATED AMINES COUPLED TO BIOLOGICAL MATERIAL | STERLING DRUG INC. (US) | 1988-02-16 | — | — | US | claimed |
| CN-112020555-B | Peptides and uses thereof | 国立大学法人新潟大学 | 2024-06-21 | — | — | CN | disclosed |
| EP-4384221-A1 | CONTROLLED DRUG RELEASE MATERIAL | Aduro Material Ab (SE) | 2024-06-19 | — | — | EP | disclosed |
| EP-3949995-B1 | PEPTIDE AND USE THEREOF | KANSAI MEDICAL UNIV EDUCATIONAL CORPORATION (JP) | 2024-06-19 | — | — | EP | disclosed |
| EP-4319556-A1 | USE OF ANTI-CLOTTING COMPOUNDS AS RODENTICIDES | Gulba, Dietrich (DE) | 2024-02-14 | — | — | EP | disclosed |
| US-11678659-B2 | Use as rodenticides of compounds that inhibit blood coagulation | GULBA DIETRICH (DE) | 2023-06-20 | — | — | US | disclosed |
| WO-2023094987-A1 | A DRUG DELIVERY COMPOSITION FOR TREATING MYOCARDIAL INFRACTION (MI) | GHAMKHARI ALIYEH (IR) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094987-A1 | A DRUG DELIVERY COMPOSITION FOR TREATING MYOCARDIAL INFRACTION (MI) | GHAMKHARI ALIYEH (IR) | 2023-06-01 | — | — | WO | disclosed |
| CN-1138632-A | Expression and secretion of hereologous proteins by yarrowia lipolytica transformants | PFIZER (US) | 1996-12-25 | — | — | CN | disclosed |
| US-5482964-A | ANTIEPILEPTIC | WARNER-LAMBERT COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
| US-5443959-A | Mixture of a protein, amino acid and magnetic particle | TOKUYAMA CORPORATION (JP) | 1995-08-22 | — | — | US | disclosed |
| WO-1991019505-A1 | MODIFIED HUMAN HEMOGLOBIN, BLOOD SUBSTITUTES CONTAINING THE SAME, AND VECTORS FOR EXPRESSING THE MODIFIED HEMOGLOBIN | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1991-12-26 | — | — | WO | disclosed |
| EP-0400010-A1 | SOLUBLE HUMAN CD4 FRAGMENTS AND USES THEREFOR | DANA-FARBER CANCER INSTITUTE (US) | 1990-12-05 | — | — | EP | disclosed |
| US-4921940-A | Process for the purification of Ti containing polycarbonate with solvent, complexing agent and water | XEROX CORPORATION (US) | 1990-05-01 | — | — | US | disclosed |
| WO-1989003222-A1 | SOLUBLE HUMAN CD4 FRAGMENTS AND USES THEREFOR | DANA-FABER CANCER INSTITUTE (US) | 1989-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11678659-B2 | Use as rodenticides of compounds that inhibit blood coagulation | PLAT, F2R, PLAUR | GLRA1 786/4885SLC6A9 2185/4885OR51E2 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.